Literature DB >> 17605128

[Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006].

A A Kurth1, J Pfeilschifter.   

Abstract

The treatment of osteoporosis and prevention of osteoporotic fractures consists of both non-drug and drug therapy. Components of non-drug therapy include the improvement of muscle strength and coordination, treatment of modifiable causes of falls, a diet rich in calcium and sufficient in calories, an adequate supply of Vitamin D and an individual assessment of drugs known to increase falls or osteoporosis. The updated DVO diagnostic and treatment guidelines for osteoporosis recommends a 30% 10-year probability for vertebral and hip fractures as an intervention threshold for drug treatment. Using epidemiological fracture data from central Europe, the guidelines provides an assessment of absolute 10-year fracture risk based on a combination of age, gender, prevalent fragility fractures, spine and total hip dual-energy x-ray absorptiometry (DXA) measurements and several other clinical risk factors.

Entities:  

Mesh:

Year:  2007        PMID: 17605128     DOI: 10.1007/s00132-007-1106-3

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  12 in total

Review 1.  Development and use of FRAX in osteoporosis.

Authors:  J A Kanis; E V McCloskey; H Johansson; A Oden; O Ström; F Borgström
Journal:  Osteoporos Int       Date:  2010-05-13       Impact factor: 4.507

2.  NICE continues to muddy the waters of osteoporosis.

Authors:  J A Kanis; J E Compston
Journal:  Osteoporos Int       Date:  2008-06-05       Impact factor: 4.507

3.  Biomechanical analysis of expansion screws and cortical screws used for ventral plate fixation on the cervical spine.

Authors:  Klaus Röhl; Bernhard Ullrich; Gerd Huber; Michael M Morlock
Journal:  Eur Spine J       Date:  2009-07-09       Impact factor: 3.134

4.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E V McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-30       Impact factor: 4.507

Review 5.  Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis.

Authors:  Zhenyu Zhou; Chen Chen; Jun Zhang; Xinran Ji; Lifeng Liu; Guichun Zhang; Xuecheng Cao; Pingshan Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

6.  Anterior vertebroplasty of adjacent levels after vertebral body replacement.

Authors:  Florian Geiger; Konstantinos Kafchitsas; Michael Rauschmann
Journal:  Eur Spine J       Date:  2011-03-30       Impact factor: 3.134

7.  Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Authors:  O Ström; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2012-12-07       Impact factor: 4.507

8.  The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Authors:  F Borgström; O Ström; J Coelho; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

Review 9.  Approaches to the targeting of treatment for osteoporosis.

Authors:  John A Kanis; Eugene V McCloskey; Helena Johansson; Anders Oden
Journal:  Nat Rev Rheumatol       Date:  2009-08       Impact factor: 20.543

10.  Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women.

Authors:  K Lippuner; H Johansson; J A Kanis; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-10-31       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.